HARROW INCORPORATED (HROW)

T. Rowe Price Group (NASDAQ:TROW) reported second-quarter 2026 adjusted diluted earnings per share of $2.57, up from $2.52 in the first quarter and $2.24 a year earlier, as higher average assets under management and investment advisory revenue outweighed increased expenses. The asset manager ended

Although the revenue and EPS for T. Rowe (TROW) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

T. Rowe (TROW) delivered earnings and revenue surprises of +1.98% and -0.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Harrow recently presented three studies at the ASRS 2026 Annual Meeting highlighting interim clinical and real-world data for IHEEZO and BYOOVIZ in retinal care. The early IHEEZO data suggesting improved post-injection comfort without added antisepsis risk could meaningfully influence how ...

NASHVILLE, Tenn., July 27, 2026 ... (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company wi…